Joseph Hernandez, M.S., MBA
Mr. Hernandez, our current Executive Chairman and member of our board of directors, was at Merck and has been involved in the management and founding of several early stage biotechnology companies, including Affymetrix, Digene (now Qiagen), Innovative Biosciences, Inc., Signal Genetics, LLC and Microlin Bio, Inc.
Dean A. Falb, Ph.D.
Dr. Falb is a Consultant at Atlas Ventures. He has broad experience in drug discovery and development in cardiovascular, oncology, inflammation, fibrosis and musculoskeletal disease areas. He has served as the Vice President of Research & Development at Stryker Regenerative Medicine, Vice President of Drug Discovery at Neogenesis (Merck), Senior Vice President of Research & Development at Praecis Pharmaceuticals, and Director of Cardiovascular Diseases at Millennium Pharmaceuticals. Dr. Falb holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University.
Hyun D. Kim, Ph.D.
Vice President of Clinical Development
Dr. Kim is an R&D leader with over 18 years pharmaceutical, biotechnology, and medical device industry and consulting experience leading R&D programs into clinical development and regulatory approvals. He previously led BMP programs at Genetics Institute and Wyeth Pharmaceuticals as well as leadership roles in early stage start-ups. He has served as Director of Product Development at Anika Therapeutics, Senior Director of R&D at Transport Pharmaceuticals, and has served as an R&D, medical affairs, and clinical and regulatory affairs consultant for Biogen Idec, Sunovion, and Teleflex. He has most recently served as the Director of R&D at Olympus Biotech where he led the development of next generation BMP-7 products. Dr. Kim holds a Ph.D. in Medical Science from Brown University, and a Sc.M. and Sc.B. in Biomedical Engineering from Brown University.